ForgingBridges is here to support your patients at every step after Attruby (acoramidis) has been prescribed.
For HCPs
Access & Support
Actor portrayals.
Support Program: ForgingBridges®
Our dedicated team is here for you
- Field Reimbursement Manager (FRM):
Works directly with you and your office staff to provide ongoing access and reimbursement support - Patient Access Liaison (PAL):
Provides personalized support to your patients and their care partners to access Attruby (acoramidis) and connect to financial assistance - ForgingBridges Specialist:
Personalized support, just a phone call away
Navigate insurance
Regardless of your patient’s insurance type, ForgingBridges can help navigate every step of the health insurance process so your patients can start and stay on Attruby (acoramidis).
ForgingBridges Copay Assistance Program*
The Copay Assistance Program may reduce out-of-pocket costs (including copays, coinsurance, and deductibles) to as little as $0 per month for Attruby (acoramidis) for eligible, commercially insured patients.*
*Eligibility criteria and Terms and Conditions apply.
Nationally, more than 90% of Medicare Part D patients have access to Attruby (acoramidis) with final coverage decision.1†
†Data as of August 2025.
Veterans Affairs Coverage
For US Military Veterans
Eligible US Veterans with ATTR-CM may receive Attruby (acoramidis) treatment through Veterans Affairs (VA) facilities via the VA Community Care Network.
VA referral required:
Veterans must receive a referral/authorization from the VA before scheduling an appointment with a Community Care Network provider.
No specialty pharmacy required:
Eligible prescriptions written by an in-network Community Care provider are adjudicated through the VA and filled by the VA pharmacy.
ATTR-CM=transthyretin amyloid cardiomyopathy; FRM=field reimbursement manager; PAL=patient access liaison; TTR=transthyretin; VA=Veterans Affairs.
Reference:
- Data on file. BridgeBio Pharma, Inc.; 2024-2026.
Important Safety Information and Indication
Important Safety Information
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).
Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.
Use in Specific Populations
Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.
Indication
Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Please see Full Prescribing Information including Patient Information.